Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Summer;8(3):120-64.

Best of the 2006 AUA Annual Meeting: Highlights from the 2006 Annual Meeting of the American Urological Association, May 20-25, 2006, Atlanta, GA

No authors listed

Best of the 2006 AUA Annual Meeting: Highlights from the 2006 Annual Meeting of the American Urological Association, May 20-25, 2006, Atlanta, GA

No authors listed. Rev Urol. 2006 Summer.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between alcohol consumption and mean total International Prostate Symptom Score (IPSS). SD, standard deviation.
Figure 2
Figure 2
Sexual inactivity, impotence, decreased libido, and PAS SFI score by IPSS baseline categories. PAS SFI, Problem Assessment Scale of the Sexual Function Inventory; IPSS, International Prostate Symptom Scale.
Figure 3
Figure 3
Comparison of the use of specific medical treatments for lower urinary tract symptoms/benign prostatic hyperplasia by primary care physicians (PCPs) and urologists. P < .0001, urologists vs PCPs, based on χ2 analysis. SAB, uroselective α1-blockers alfuzosin and tamsulosin; NSAB, all other α1-blockers; 5ARI, 5α-reductase inhibitor; Combo, AB + 5ARI; AC, anticholinergic.
Figure 4
Figure 4
Cumulative incidence of overall benign prostatic hyperplasia progression with alfuzosin versus placebo.
Figure 5
Figure 5
ALTESS and MTOPS: incidence of benign prostatic hyperplasia-related surgery by prostate-specific antigen tertile. ALTESS, Alfuzosin Long-Term Efficacy and Safety Study; MTOPS, Medical Therapy of Prostate Symptoms.
Figure 6
Figure 6
ALTESS: impact of baseline variables on the risk of benign prostatic hyperplasia (BPH) progression. ALTESS, Alfuzosin Long-Term Efficacy and Safety Study; PSA, prostate-specific antigen level; DRE, digital rectal examination-estimated prostate size; IPSS, International Prostate Symptom Score; PVR, postvoid residual volume; AUR, acute urinary retention.
Figure 7
Figure 7
Change in International Prostate Symptom Score (IPSS) at 6 and 12 weeks with tadalafil (5 and 20 mg) compared with placebo. LS, least square. *Tadalafil compared with placebo; one-sided P values from analysis of covariance models with terms for treatment group, geographic region, previous α-blocker use, and baseline IPSS value; last observation carried forward (LOCF) analysis for weeks 0–12.
Figure 8
Figure 8
Effects of daily alfuzosin (10 mg), sildenafil (25 mg), or both on (A) lower urinary tract symptoms, according to International Prostate Symptom Score (IPSS), and (B) erectile dysfunction, according to the International Index of Erectile Function (IIEF) (higher scores indicate better function).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Melman A, Bar-Chama N, McCullough AR, et al. Results of the first human trial for genetransfer therapy for the treatment of erectile dysfunction [abstract 686] J Urol. 2006;175(4 suppl):222.
    1. Lowe D, Hoffmann JD, Christ GJ, et al. Efficacy of weekly administration of hSlo (hMaxi-K) gene transfer for treatment of erectile dysfunction in aging rats [abstract 688] J Urol. 2006;175(4 suppl):223.
    1. Prince W, Campbell AS, Tong W, et al. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects [abstract 924] J Urol. 2006;175(4 suppl):299.
    1. Kaufman J, Dietrich JW. Safety and efficacy of avanafil, a new phosphodiesterase type-5 inhibitor for treating erectile dysfunction [abstract 923] J Urol. 2006;175(4 suppl):299.
    1. Rosen RC, Marks LS, McVary KT, et al. Association between ejaculatory dysfunction and therapy among men enrolled in the BPH registry and patient survey [abstract 921] J Urol. 2006;175(4 suppl):298.

LinkOut - more resources